Brussels, Belgium. (PRWEB) August 10, 2006
Euroscreen s.a. announced today that it filed a complaint in the Osaka District Court (case number H18 (wa) 7760) alleging that Ono Pharmaceuticals Co., Ltd. infringed a basic CCR5 patent (JP Patent No. 3288384) in the discovery of Ono's CCR5 drug candidates. Ono has partnered these candidates with GSK.
“Euroscreen licenses out Euroscreen's CCR5 patent portfolio together with the portfolio of a patent licensor. Euroscreen and its licensor pioneered CCR5 research in the 1990s, and have carefully evaluated the patent situation, firmly believe that Ono infringed this Japanese patent. The invention was the starting point for the development of all small molecule CCR5 blocking candidates, ONO-4128 and certain associated compounds," said Dr. Alfred Gray, Euroscreen's Vice President for Business Development. The basic inventions that underlie the suit form the basis for essentially all of CCR5 drug discovery research. Therefore, Ono or any other company should not be free to expropriate the use of the patent claims that were created at great risk and cost to the inventors."
Euroscreen already non-exclusively licensed CCR5 patent rights to Pfizer Inc in 2002, to enable similar drug discovery research.
About Euroscreen s.a. – http://www.euroscreen.com
Euroscreen is a preclinical-stage biopharmaceutical company focusing on the discovery, development and partnering of small molecule drugs for unmet medical needs. Euroscreen is developing a pipeline of compounds targeting G protein-coupled receptors (GPCRs) using 12 years of experience in research and commercialization of this critical class of drug targets in association with the Institute of Interdisciplinary Research (IRIBHM) of the University of Brussels. Euroscreen's AequoScreen(tm) cellular assay platform is used extensively in its screening of GPCRs for candidate drugs which are partnered during preclinical development.
The Company has developed a broad GPCR patent portfolio for licensing to biopharmaceutical companies. Such patents address targets such as CCR5, Chemerin receptor, GPR43, GPR7/8, FPRL2, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2 for type II diabetes. Euroscreen is able to offer intellectual property rights to companies for the development of therapeutic drugs that act through the above-mentioned targets. For more information regarding the Euroscreen’s portfolio and the associated licensing terms, please contact Dr. Vincent Lannoy.
Euroscreen pursues a dual platform strategy of combining its drug discovery business with its products and services business unit which serves biopharmaceutical companies around the world. Euroscreen focuses on internal targets in the inflammation area as well as several partnered preclinical-stage collaborations with biopharmaceutical partners. The company has research, product distribution and licensing partnerships with Alchemia, Amersham/GE Healthcare, Cephalon, ChemDiv, Evotec, ICOS, Medarex, Merck & Co, Novartis, Pfizer Inc, and Solvay. Euroscreen is a privately held company based in Brussels, Belgium.
For further information, please contact:
Euroscreen s.a. Tel: +32 71 348 500
Al Gray, Ph.D. VP Business Development
Vincent Lannoy, Ph.D. Business Development and Licensing Manager